| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | - | - | - | 0 | 40.989.365 | 114.622.573 |
| Total Income - EUR | - | - | - | - | - | - | - | 0 | 41.110.956 | 114.823.214 |
| Total Expenses - EUR | - | - | - | - | - | - | - | 1.236 | 40.966.785 | 112.353.303 |
| Gross Profit/Loss - EUR | - | - | - | - | - | - | - | -1.236 | 144.171 | 2.469.911 |
| Net Profit/Loss - EUR | - | - | - | - | - | - | - | -1.236 | -332.886 | 1.920.384 |
| Employees | - | - | - | - | - | - | - | 0 | 80 | 154 |
Check the financial reports for the company - Sandoz Pharmaceuticals S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | - | - | - | 0 | 1.784.210 | 1.190.157 |
| Current Assets | - | - | - | - | - | - | - | 20.037 | 55.698.633 | 82.401.766 |
| Inventories | - | - | - | - | - | - | - | 0 | 16.941.183 | 23.233.339 |
| Receivables | - | - | - | - | - | - | - | 0 | 38.742.180 | 55.994.841 |
| Cash | - | - | - | - | - | - | - | 20.037 | 15.270 | 3.173.586 |
| Shareholders Funds | - | - | - | - | - | - | - | 19.042 | 20.745.518 | 22.665.826 |
| Social Capital | - | - | - | - | - | - | - | 20.278 | 17.391.625 | 17.294.428 |
| Debts | - | - | - | - | - | - | - | 995 | 36.234.299 | 60.221.816 |
| Income in Advance | - | - | - | - | - | - | - | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4646 - 4646" | |||||||||
| CAEN Financial Year |
4646
|
|||||||||
Comments - Sandoz Pharmaceuticals S.r.l.